摘要
目的:评价16 mg坎地沙坦西酯治疗轻中度原发性高血压患者的有效性和安全性。方法:采用随机、双盲、平行对照的研究方法,入选患者65例,随机接受坎地沙坦西酯16 mg.d-1(n=33)或8 mg.d-1(n=32)治疗,共8周,并对其中的37例患者于治疗前后进行24 h动态血压监测。结果:治疗8周末,16 mg组和8 mg组的收缩压分别下降(10.9±11.5)mmHg和(11.5±15.1)mmHg,舒张压分别下降(12.9±11.3)mmHg和(10.5±7.8)mmHg;两组的降压总有效率分别为70%和61.3%。动态血压监测显示,16 mg组和8 mg组的收缩压谷峰比值分别为73%和47%,舒张压为65%和47%。两组的不良事件发生率无统计学差异。结论:高剂量坎地沙坦西酯16 mg.d-1治疗轻中度原发性高血压安全有效,患者耐受性好。
Objective：To evaluate the antihypertensive efficacy and safety of candesartan cilexetil at a larger dose of 16mg in patients with mild to moderate essential hypertension.Methods： In a randomized,double-blind,and parallel-controlled trial,65 hypertensive patients were randomly assigned to receive candesartan cilexetil at dose of 16mg·d-1（n=33） or 8mg·d-1（n=32） to control blood pressure for an 8-week active-treatment period.Thirty-seven patients from the two groups underwent an ambulatory blood pressure monitoring（ABPM） before and after 8-week treatment.Results： After 8-week treatment,the mean systolic blood pressure（SBP） and mean diastolic blood pressure（DBP） were significantly reduced by（10.9±11.5） and（12.9±11.3） mmHg in 16mg group,while by（11.5±15.1）and（10.5±7.8） mmHg in 8mg group,respectively.The efficacy rate was 70% and 61.3% in 16mg and 8mg groups.The ABPM values showed a significant reduction in both groups.The mean trough/peak（T/P） ratio of SBP was 73% and 47%,and that of DBP was 65% and 47%,respectively,in 16 and 8mg groups.The incidence of overall adverse events showed no statistical difference in both groups.Conclusion： Candesartan cilexetil once daily at a larger dose of 16mg is safe and effective in the treatment of mild to moderate essential hypertension,and the tolerability is well at this dose.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2008年第21期1873-1876,共4页
Chinese Journal of New Drugs
关键词
坎地沙坦西酯
高血压
动态血压监测
candesartan cilexetil
hypertension
ambulatory blood pressure monitoring
